Valeo Financial Advisors LLC Has $3.20 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Valeo Financial Advisors LLC boosted its position in shares of Danaher Co. (NYSE:DHR) by 9.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,812 shares of the conglomerate’s stock after purchasing an additional 1,152 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Danaher were worth $3,199,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in DHR. Tsfg LLC lifted its holdings in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares during the period. Cape Investment Advisory Inc. bought a new position in shares of Danaher in the 4th quarter worth $25,000. BKM Wealth Management LLC acquired a new stake in shares of Danaher during the fourth quarter worth $27,000. Wetzel Investment Advisors Inc. bought a new stake in Danaher in the fourth quarter valued at about $29,000. Finally, Rakuten Securities Inc. acquired a new position in Danaher in the fourth quarter valued at about $36,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 0.2 %

DHR traded down $0.41 during trading on Wednesday, reaching $240.00. 1,935,736 shares of the stock were exchanged, compared to its average volume of 2,868,707. The stock has a market cap of $177.77 billion, a P/E ratio of 41.14, a price-to-earnings-growth ratio of 3.82 and a beta of 0.84. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The stock’s 50 day moving average price is $255.88 and its two-hundred day moving average price is $246.95. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $269.11.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the previous year, the company posted $2.36 EPS. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. Equities analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Robert W. Baird increased their price target on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Evercore ISI decreased their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday. Bank of America upped their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Jefferies Financial Group began coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $268.67.

Insider Activity at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Matthew Mcgrew sold 46,377 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $7,441,441.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 148,783 shares of company stock worth $37,536,717. Insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.